This week’s cover

We had one worldwide cover this week. And it featured some very good news.
 
GLP-1 receptor agonists such as Ozempic and Wegovy started as treatments for diabetes and obesity. That alone would have qualified them as wonder drugs. Now they are being found to help with cardiovascular and kidney disease, too, and are being tested for use against Alzheimer’s and addiction. Researchers are even talking, in hushed tones, of their anti-ageing effects.

They may turn out to be one of the most successful classes of drugs in history.